DocGo (DCGO)
Market Price (2/9/2026): $0.7815 | Market Cap: $76.4 MilSector: Health Care | Industry: Health Care Facilities
DocGo (DCGO)
Market Price (2/9/2026): $0.7815Market Cap: $76.4 MilSector: Health CareIndustry: Health Care Facilities
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -58% | Weak multi-year price returns2Y Excs Rtn is -117%, 3Y Excs Rtn is -161% | Penny stockMkt Price is 0.8 |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 16%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 14% | Meaningful short interestShort Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 10.66 | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -64 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -17% |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -33% | Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -47%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is 0.3%, Rev Chg QQuarterly Revenue Change % is -49% | |
| Attractive yieldFCF Yield is 68% | Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -72% | |
| Megatrend and thematic driversMegatrends include Digital Health & Telemedicine. Themes include Telehealth Platforms, and Remote Patient Monitoring. | Key risksDCGO key risks include [1] a securities class action lawsuit and severe mismanagement of a major no-bid contract, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -58% |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 16%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 14% |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -33% |
| Attractive yieldFCF Yield is 68% |
| Megatrend and thematic driversMegatrends include Digital Health & Telemedicine. Themes include Telehealth Platforms, and Remote Patient Monitoring. |
| Weak multi-year price returns2Y Excs Rtn is -117%, 3Y Excs Rtn is -161% |
| Meaningful short interestShort Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 10.66 |
| Penny stockMkt Price is 0.8 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -64 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -17% |
| Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -47%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is 0.3%, Rev Chg QQuarterly Revenue Change % is -49% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -72% |
| Key risksDCGO key risks include [1] a securities class action lawsuit and severe mismanagement of a major no-bid contract, Show more. |
Qualitative Assessment
AI Analysis | Feedback
DocGo (DCGO) stock has lost about 30% since 10/31/2025 because of the following key factors:
1. Significant Revenue Decline from Wind-Down of Migrant-Related Programs and Challenges in Cost Structure Adjustment.DocGo experienced a substantial year-over-year revenue decline, primarily attributed to the conclusion of migrant-related programs. For the third quarter of 2025, total revenue dropped to $70.8 million from $138.7 million in the third quarter of 2024, with this decrease "entirely due to the wind-down of migrant-related programs." This also contributed to declines in the second quarter of 2025. The company faced difficulties adjusting its cost structure following the unsustainable revenue stream from these large, temporary contracts, impacting its overall profitability.
2. Downward Revision of Full-Year 2025 Financial Guidance.The company significantly lowered its financial outlook for the full year 2025. Following its Q3 2025 earnings, DocGo revised its adjusted EBITDA guidance downward to a loss ranging from $30 million to $20 million, a considerable shift from previous projections of a positive 5%. Additionally, full-year 2025 revenue guidance was reduced to $300 million - $330 million, a substantial decrease from the earlier expectation of $410 million - $450 million, partly due to the removal of non-migrant municipal population health revenue from its guidance.
Show more
1. Significant Revenue Decline from Wind-Down of Migrant-Related Programs and Challenges in Cost Structure Adjustment.DocGo experienced a substantial year-over-year revenue decline, primarily attributed to the conclusion of migrant-related programs. For the third quarter of 2025, total revenue dropped to $70.8 million from $138.7 million in the third quarter of 2024, with this decrease "entirely due to the wind-down of migrant-related programs." This also contributed to declines in the second quarter of 2025. The company faced difficulties adjusting its cost structure following the unsustainable revenue stream from these large, temporary contracts, impacting its overall profitability.
2. Downward Revision of Full-Year 2025 Financial Guidance.The company significantly lowered its financial outlook for the full year 2025. Following its Q3 2025 earnings, DocGo revised its adjusted EBITDA guidance downward to a loss ranging from $30 million to $20 million, a considerable shift from previous projections of a positive 5%. Additionally, full-year 2025 revenue guidance was reduced to $300 million - $330 million, a substantial decrease from the earlier expectation of $410 million - $450 million, partly due to the removal of non-migrant municipal population health revenue from its guidance.
Show more
Stock Movement Drivers
Fundamental Drivers
The -28.7% change in DCGO stock from 10/31/2025 to 2/8/2026 was primarily driven by a -16.5% change in the company's P/S Multiple.| (LTM values as of) | 10312025 | 2082026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.09 | 0.78 | -28.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 436 | 368 | -15.6% |
| P/S Multiple | 0.2 | 0.2 | -16.5% |
| Shares Outstanding (Mil) | 99 | 98 | 1.1% |
| Cumulative Contribution | -28.7% |
Market Drivers
10/31/2025 to 2/8/2026| Return | Correlation | |
|---|---|---|
| DCGO | -28.7% | |
| Market (SPY) | 1.3% | 47.6% |
| Sector (XLV) | 9.3% | 29.3% |
Fundamental Drivers
The -42.8% change in DCGO stock from 7/31/2025 to 2/8/2026 was primarily driven by a -29.3% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 7312025 | 2082026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.36 | 0.78 | -42.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 521 | 368 | -29.3% |
| P/S Multiple | 0.3 | 0.2 | -22.2% |
| Shares Outstanding (Mil) | 102 | 98 | 3.9% |
| Cumulative Contribution | -42.8% |
Market Drivers
7/31/2025 to 2/8/2026| Return | Correlation | |
|---|---|---|
| DCGO | -42.8% | |
| Market (SPY) | 9.6% | 40.6% |
| Sector (XLV) | 21.5% | 22.4% |
Fundamental Drivers
The -84.1% change in DCGO stock from 1/31/2025 to 2/8/2026 was primarily driven by a -71.2% change in the company's P/S Multiple.| (LTM values as of) | 1312025 | 2082026 | Change |
|---|---|---|---|
| Stock Price ($) | 4.89 | 0.78 | -84.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 695 | 368 | -47.0% |
| P/S Multiple | 0.7 | 0.2 | -71.2% |
| Shares Outstanding (Mil) | 102 | 98 | 4.4% |
| Cumulative Contribution | -84.1% |
Market Drivers
1/31/2025 to 2/8/2026| Return | Correlation | |
|---|---|---|
| DCGO | -84.1% | |
| Market (SPY) | 15.8% | 27.8% |
| Sector (XLV) | 8.8% | 20.0% |
Fundamental Drivers
The -92.2% change in DCGO stock from 1/31/2023 to 2/8/2026 was primarily driven by a -90.5% change in the company's P/S Multiple.| (LTM values as of) | 1312023 | 2082026 | Change |
|---|---|---|---|
| Stock Price ($) | 10.00 | 0.78 | -92.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 453 | 368 | -18.8% |
| P/S Multiple | 2.2 | 0.2 | -90.5% |
| Shares Outstanding (Mil) | 99 | 98 | 1.2% |
| Cumulative Contribution | -92.2% |
Market Drivers
1/31/2023 to 2/8/2026| Return | Correlation | |
|---|---|---|
| DCGO | -92.2% | |
| Market (SPY) | 76.2% | 26.7% |
| Sector (XLV) | 23.8% | 19.7% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| DCGO Return | -7% | -24% | -21% | -24% | -79% | -21% | -93% |
| Peers Return | 25% | -23% | 1% | -8% | 2% | 14% | 4% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | -1% | 81% |
Monthly Win Rates [3] | |||||||
| DCGO Win Rate | 50% | 42% | 42% | 50% | 25% | 0% | |
| Peers Win Rate | 56% | 40% | 50% | 43% | 52% | 70% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| DCGO Max Drawdown | -24% | -44% | -32% | -49% | -79% | -22% | |
| Peers Max Drawdown | -23% | -45% | -22% | -30% | -19% | -2% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -1% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: PNTG, EHAB, OPCH, CHE, AMN.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 2/6/2026 (YTD)
How Low Can It Go
| Event | DCGO | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -56.5% | -25.4% |
| % Gain to Breakeven | 129.8% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
Compare to PNTG, EHAB, OPCH, CHE, AMN
In The Past
DocGo's stock fell -56.5% during the 2022 Inflation Shock from a high on 10/13/2022. A -56.5% loss requires a 129.8% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About DocGo (DCGO)
DocGo, Inc. provides mobile health and medical transportation services for various health care providers in the United States and the United Kingdom. The company's transportation services include emergency response services; and non-emergency transport services comprise ambulance and wheelchair transportation services. It also offers mobile health services through its platform that are performed at home and offices; COVID-19 testing; and event services, which include on-site healthcare support at sporting events and concerts. DocGo, Inc. was incorporated in 2015 and is headquartered in New York, New York.
AI Analysis | Feedback
Here are 1-3 brief analogies to describe DocGo (DCGO):
- Amazon for in-person medical care delivered to your location.
- Uber for mobile urgent and primary care visits.
- A MinuteClinic or urgent care center that comes to your home or workplace.
AI Analysis | Feedback
- Mobile Health Services: Provides on-demand, in-home or in-workplace urgent and primary medical care, including chronic condition management, delivered by medical professionals directly to patients.
- Medical Transportation Services: Offers a range of non-emergency medical transportation, including basic and advanced life support ambulance services, for patients requiring transit between locations.
- Event Medical Services: Delivers onsite medical staffing and support for various events, ensuring immediate medical attention and emergency response capability.
AI Analysis | Feedback
DocGo (DCGO) primarily sells its mobile health and medical transport services to other companies and governmental entities (B2B and B2G), rather than directly to individuals. Their services are often provided to individuals who are part of these larger organizational contracts.
Its major customer, explicitly identified in its financial filings due to revenue concentration, is:
- The City of New York: For the year ended December 31, 2023, approximately 49% of DocGo's total revenue was derived from its contract to provide medical services to the City of New York. This is a governmental entity and does not have a public stock symbol.
DocGo also serves a variety of other organizations, though specific names of other "major" customers are not typically disclosed in public filings unless they represent a significant portion of the company's revenue. These customer categories include:
- Healthcare systems and hospitals
- Employers
- Other governmental agencies (state and federal)
- Event organizers
AI Analysis | Feedback
null
AI Analysis | Feedback
Lee Bienstock, Chief Executive Officer
Mr. Bienstock became CEO of DocGo in September 2023, having previously served as the company's President and Chief Operating Officer. Before joining DocGo in 2022, he spent ten years at Google, where his most recent role was Global Head of Enterprise Partnerships for Devices and Services. He holds an MBA from the Wharton School at the University of Pennsylvania and a BS from Cornell University.
Norman Rosenberg, Treasurer and Chief Financial Officer
Mr. Rosenberg became CFO of DocGo Inc. in January 2023, and Treasurer in September 2023, after joining Ambulnz Holdings, LLC as CFO in January 2020. Prior to Ambulnz, he spent five years at AmTrust Financial, Inc., serving in various capacities, including president of their direct-to-consumer division and CFO of fee companies. In his CFO role at AmTrust, he oversaw the divestitures of several non-core units, generating over $1 billion in proceeds. Mr. Rosenberg has also held CFO positions at companies such as KDDI Global, Marsh, Inc., and IDT Telecom. Earlier in his career, he worked as an equity analyst for Standard & Poor's Corporation.
Dr. James Powell, CEO, Clinical Practice Group
Dr. Powell is a board-certified Internist with over 20 years of experience as a physician executive for non-profit organizations that focus on underserved populations. Before his role at DocGo, he was the CEO of Long Island Select Healthcare (LISH), a federally qualified health center, where he successfully implemented integrative community programs and contributed to significant cost savings as Treasurer of their Accountable Care Organization (ACO). He has also served as a medical advisor for startup health IT companies specializing in telemedicine, AI, and remote patient monitoring services.
Andre Oberholzer, Executive Vice President of Strategy
Mr. Oberholzer currently serves as DocGo's Executive Vice President of Strategy. He previously held the position of CFO for DocGo from 2015 until January 2023, bringing over 30 years of senior financial and operational experience to the company. Prior to DocGo, he served as CFO for various companies, from startups to large global enterprises, including a division of Altegrity (2006-2012), WageWorks (2005-2006), and Philips Electronics (EES) and Philips Healthcare (Customer Service) (2001-2005), where his responsibilities included restructuring, M&A integration, and new business modeling.
Ely D. Tendler, General Counsel and Secretary of Board of Directors
Mr. Tendler has been General Counsel of DocGo and a member of its board of directors since 2015. He is also the Principal of Ely D. Tendler Strategic and Legal Services and has more than 25 years of experience as an attorney, with extensive transactional, operational, and managerial expertise.
AI Analysis | Feedback
The key risks to DocGo's business include:- Legal and Governance Issues: DocGo faces significant legal and governance challenges, including a securities class action lawsuit that survived dismissal, alleging misrepresentations about contracts. An audit of a $432 million no-bid contract in New York City revealed that 80% of initial payments were unsupported or unallowable, suggesting systemic mismanagement and raising questions about the company's operational and ethical conduct. These issues, alongside the past revelation of the former CEO fabricating educational credentials, have severely eroded investor trust and could lead to substantial financial liabilities, potentially exceeding $50 million, and even risk the depletion of cash reserves or a Chapter 11 filing.
- Reliance on Government Contracts and Revenue Decline: The company's historical revenue growth was heavily reliant on large government contracts, particularly for COVID-19 testing, vaccinations, and migrant-related care. However, these high-margin government contracts have largely wound down since 2023, leading to a significant decline in total revenue. DocGo reported a 39% drop in Q4 2024 revenue and a projected full-year 2025 revenue of $315 million to $320 million, a sharp decline from previous years. The company is in a critical transition phase, attempting to pivot to higher-margin, recurring payer and provider partnerships, but this shift presents execution risk and uncertainty in replacing lost revenue.
- History of Losses and Challenges to Achieving Profitability: DocGo has a history of operating losses and anticipates that operating expenses will increase significantly in the foreseeable future, making it challenging to achieve or sustain profitability. The company reported a GAAP net loss of $29.7 million in Q3 2025 and projected a full-year 2025 adjusted EBITDA loss of $25 million to $28 million. Successfully managing growth, maintaining and expanding client relationships, recovering upfront costs, and controlling significant labor expenses are critical for the company to reverse its profitability trend.
AI Analysis | Feedback
- The increasing trend of large health insurance payers and integrated health systems to vertically integrate and develop their own in-house mobile health and home-based care capabilities. This reduces the addressable market for third-party providers like DocGo and can lead to less favorable contracting terms or reduced demand for outsourced services as potential clients become direct competitors. Evidence includes major health systems expanding "Hospital at Home" programs and payers acquiring or building their own care delivery assets.
- Intensifying competition from well-funded, specialized mobile health providers (e.g., DispatchHealth) and the expansion of technology-driven non-emergency medical transportation (NEMT) services by ride-sharing companies (e.g., Uber Health, Lyft Healthcare). This increases competitive pressure on DocGo's core mobile health and NEMT segments, potentially impacting market share, pricing power, and profitability.
AI Analysis | Feedback
DocGo (DCGO) operates in the mobile health and medical transportation sectors, and also offers remote patient monitoring. The addressable markets for its main products and services are as follows:
- Mobile Health Services: DocGo's Mobile Health segment, which includes in-home care, telehealth services, and population health programs, has a total addressable market of approximately $265 billion. This market size primarily pertains to the U.S.
- Medical Transportation Services: DocGo, through its Ambulnz brand, provides a full range of medical transportation services. The total addressable market for this segment is estimated to be between $7 billion and $13 billion. This market size primarily pertains to the U.S.
-
Remote Patient Monitoring (RPM) & Chronic Disease Management: DocGo offers Total Virtual Care Management (VCM) and Remote Patient Monitoring services. The global remote patient monitoring market size varies across different reports:
- One estimate places the global RPM devices market at approximately $17 billion in 2024, projected to grow to $57.5 billion by 2034. North America held a 40% market share in 2024, with the U.S. market reaching $6.3 billion in 2024.
- Another report estimates the global remote patient monitoring system market size at $22.03 billion in 2024, projected to reach $110.71 billion by 2033. North America accounted for a 40.5% share of this market in 2024.
- The global remote patient monitoring market was also valued at $43.22 billion in 2024 and is expected to grow to $137.26 billion by 2033. North America is identified as the most significant market shareholder in this segment.
AI Analysis | Feedback
DocGo (DCGO) is strategically pivoting its business focus to drive future revenue growth over the next 2-3 years, moving away from its declining migrant-related programs. The company's expected growth drivers are primarily centered on expanding its core mobile health and medical transportation services, enhanced by technological integration and strategic acquisitions.
Here are 3-5 expected drivers of future revenue growth for DocGo:
- Expansion of Care Gap Closure Programs: DocGo is significantly expanding its care gap closure programs, which involve proactive in-home health assessments and services to address gaps in patient care. The company has seen substantial progress, more than doubling assigned lives from Q2 to Q3 2024 to over 500,000 patients and exceeding 1.2 million assigned lives to engage with since the program's inception by Q2 2025. DocGo aims to complete over 31,000 care gap visits by the end of 2025 and increase that number to more than 54,000 by the end of 2026. This expansion includes launching new programs in regions like Southern California and broadening partnerships with national insurers.
- Growth in Medical Transportation Services: DocGo anticipates continued revenue growth from its medical transportation segment. In the third quarter of 2024, transportation services revenue saw a 2% increase compared to the prior year. The company launched services for a major new medical transportation customer in the New York market in July 2025, expecting this to drive its highest-ever revenues and trip volumes in this vertical during the second half of 2025. DocGo has also set a target for 15% annual revenue growth in its transportation segment for 2025.
- Acquisition and Integration of SteadyMD: The acquisition of SteadyMD, a virtual care platform, is expected to be a notable contributor to revenue growth. This acquisition, completed in October 2025, is projected to add approximately $25 million in revenue by 2025 and is anticipated to become EBITDA positive by 2026, expanding DocGo's telehealth services across all 50 states.
- Geographic Expansion of Core Services: Beyond existing markets, DocGo plans to expand its core mobile health services, particularly its payer and provider business and care gap closure programs, into more than a half dozen new states by the end of 2026. This broader reach for its services, including mobile phlebotomy added through the acquisition of PTI Health in 2024, aims to tap into a larger market for proactive healthcare.
AI Analysis | Feedback
Share Repurchases
- DocGo authorized a share repurchase program of up to $40 million in May 2022, which expired in November 2023.
- A new share repurchase program was approved in January 2024, authorizing repurchases of up to $36 million of its common stock over a six-month period ending July 30, 2024.
- As of May 8, 2024, DocGo had repurchased approximately 2.7 million shares under the 2024 program at an average net price of $3.69 per share, with approximately $26 million remaining under the authorization.
Share Issuance
- DocGo became a publicly traded company on December 15, 2021, after Motion Acquisition Corp. changed its name to DocGo Inc.
- A registration statement filed in December 2021, and declared effective in January 2022, included the registration for resale of up to 28,234,175 shares of common stock and warrants.
- The number of outstanding shares saw an increase of 5.15% in 2023, reaching 104.05 million shares, followed by decreases of 2.06% in 2024 and 2.92% in 2025.
Outbound Investments
- In October 2025, DocGo acquired the virtual care platform SteadyMD, Inc., as part of an effort to expand its telehealth services across all 50 states.
Capital Expenditures
- Capital expenditures for the 12 months ending in early 2025 were approximately $4.02 million.
- Reported capital expenditures were $2.2 million for the first quarter of 2025 and $667,173 for the fourth quarter of 2024.
- Investments are focused on positioning the company for future growth, including transitioning from migrant-related revenues to core mobile health revenue and enhancing its technology-enabled mobile health services.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| DocGo Earnings Notes | 12/16/2025 | |
| Can DocGo Stock Recover If Markets Fall? | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 25.33 |
| Mkt Cap | 0.9 |
| Rev LTM | 1,789 |
| Op Inc LTM | 53 |
| FCF LTM | 139 |
| FCF 3Y Avg | 153 |
| CFO LTM | 160 |
| CFO 3Y Avg | 188 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 3.7% |
| Rev Chg 3Y Avg | 3.1% |
| Rev Chg Q | 3.5% |
| QoQ Delta Rev Chg LTM | 0.9% |
| Op Mgn LTM | 5.5% |
| Op Mgn 3Y Avg | 5.3% |
| QoQ Delta Op Mgn LTM | -0.4% |
| CFO/Rev LTM | 7.9% |
| CFO/Rev 3Y Avg | 6.1% |
| FCF/Rev LTM | 6.9% |
| FCF/Rev 3Y Avg | 5.5% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 0.9 |
| P/S | 0.8 |
| P/EBIT | 16.9 |
| P/E | 10.8 |
| P/CFO | 12.2 |
| Total Yield | 0.2% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | 8.7% |
| D/E | 0.3 |
| Net D/E | 0.2 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 7.4% |
| 3M Rtn | 16.2% |
| 6M Rtn | 17.2% |
| 12M Rtn | -4.3% |
| 3Y Rtn | -16.3% |
| 1M Excs Rtn | 4.9% |
| 3M Excs Rtn | 9.4% |
| 6M Excs Rtn | 11.6% |
| 12M Excs Rtn | -20.9% |
| 3Y Excs Rtn | -88.1% |
Segment Financials
Revenue by Segment| $ Mil | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
| Mobile Health Services | 443 | 326 | 234 | 31 |
| Transportation Services | 181 | 115 | 84 | 63 |
| Corporate | 0 | 0 | ||
| Total | 624 | 441 | 319 | 94 |
| $ Mil | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
| Mobile Health Services | 80 | 93 | 42 | 5 |
| Transportation Services | 4 | -15 | -26 | -19 |
| Corporate | -69 | -56 | ||
| Total | 15 | 22 | 15 | -15 |
| $ Mil | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
| Mobile Health Services | 281 | 117 | 80 | 12 |
| Transportation Services | 132 | 119 | 229 | 89 |
| Corporate | 78 | 158 | ||
| Total | 490 | 393 | 310 | 100 |
Price Behavior
Price Behavior
| Market Price | $0.78 | |
| Market Cap ($ Bil) | 0.1 | |
| First Trading Date | 11/08/2021 | |
| Distance from 52W High | -86.1% | |
| 50 Days | 200 Days | |
| DMA Price | $0.90 | $1.33 |
| DMA Trend | down | down |
| Distance from DMA | -13.2% | -41.6% |
| 3M | 1YR | |
| Volatility | 68.8% | 80.8% |
| Downside Capture | 459.48 | 321.96 |
| Upside Capture | 205.00 | 84.93 |
| Correlation (SPY) | 42.9% | 26.3% |
DCGO Betas & Captures as of 1/31/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 2.36 | 1.51 | 2.31 | 2.55 | 1.10 | 1.22 |
| Up Beta | 2.96 | 1.53 | 2.57 | 4.53 | 0.68 | 1.12 |
| Down Beta | -0.83 | -0.91 | 0.61 | 2.00 | 0.55 | 0.89 |
| Up Capture | 282% | 144% | 187% | 107% | 70% | 48% |
| Bmk +ve Days | 11 | 22 | 34 | 71 | 142 | 430 |
| Stock +ve Days | 8 | 14 | 20 | 44 | 94 | 322 |
| Down Capture | 664% | 405% | 330% | 257% | 164% | 112% |
| Bmk -ve Days | 9 | 19 | 27 | 54 | 109 | 321 |
| Stock -ve Days | 12 | 26 | 39 | 76 | 144 | 395 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with DCGO | |
|---|---|---|---|---|
| DCGO | -83.9% | 81.0% | -1.87 | - |
| Sector ETF (XLV) | 7.7% | 17.3% | 0.27 | 20.1% |
| Equity (SPY) | 15.4% | 19.4% | 0.61 | 27.5% |
| Gold (GLD) | 73.9% | 24.8% | 2.19 | -3.4% |
| Commodities (DBC) | 8.9% | 16.6% | 0.34 | 2.9% |
| Real Estate (VNQ) | 4.6% | 16.5% | 0.10 | 17.8% |
| Bitcoin (BTCUSD) | -27.1% | 44.7% | -0.57 | 19.6% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with DCGO | |
|---|---|---|---|---|
| DCGO | -39.8% | 70.3% | -0.54 | - |
| Sector ETF (XLV) | 8.1% | 14.5% | 0.37 | 22.1% |
| Equity (SPY) | 14.4% | 17.0% | 0.68 | 31.8% |
| Gold (GLD) | 21.4% | 16.9% | 1.03 | 1.9% |
| Commodities (DBC) | 11.5% | 18.9% | 0.49 | 2.1% |
| Real Estate (VNQ) | 5.0% | 18.8% | 0.17 | 22.1% |
| Bitcoin (BTCUSD) | 16.1% | 58.0% | 0.49 | 19.4% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with DCGO | |
|---|---|---|---|---|
| DCGO | -22.4% | 70.3% | -0.54 | - |
| Sector ETF (XLV) | 10.9% | 16.5% | 0.54 | 22.1% |
| Equity (SPY) | 15.4% | 17.9% | 0.74 | 31.8% |
| Gold (GLD) | 15.7% | 15.5% | 0.84 | 1.9% |
| Commodities (DBC) | 8.0% | 17.6% | 0.37 | 2.1% |
| Real Estate (VNQ) | 6.0% | 20.7% | 0.25 | 22.1% |
| Bitcoin (BTCUSD) | 68.7% | 66.7% | 1.08 | 19.4% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 11/10/2025 | -0.9% | -13.3% | -15.3% |
| 8/7/2025 | 12.9% | 17.3% | 12.9% |
| 5/8/2025 | -39.9% | -39.9% | -31.3% |
| 2/27/2025 | -21.2% | -25.3% | -32.7% |
| 11/7/2024 | 10.8% | 15.8% | 14.1% |
| 8/7/2024 | 21.4% | 8.7% | 21.4% |
| 5/8/2024 | -12.1% | -4.0% | -11.1% |
| 1/16/2024 | 4.4% | 7.2% | 13.4% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 8 | 8 | 7 |
| # Negative | 7 | 7 | 8 |
| Median Positive | 10.6% | 14.1% | 13.4% |
| Median Negative | -12.1% | -6.9% | -15.8% |
| Max Positive | 21.4% | 18.6% | 21.8% |
| Max Negative | -39.9% | -39.9% | -32.7% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 09/30/2025 | 11/10/2025 | 10-Q |
| 06/30/2025 | 08/07/2025 | 10-Q |
| 03/31/2025 | 05/08/2025 | 10-Q |
| 12/31/2024 | 02/27/2025 | 10-K |
| 09/30/2024 | 11/07/2024 | 10-Q |
| 06/30/2024 | 08/07/2024 | 10-Q |
| 03/31/2024 | 05/08/2024 | 10-Q |
| 12/31/2023 | 02/28/2024 | 10-K |
| 09/30/2023 | 11/06/2023 | 10-Q |
| 06/30/2023 | 08/08/2023 | 10-Q |
| 03/31/2023 | 05/09/2023 | 10-Q |
| 12/31/2022 | 03/14/2023 | 10-K |
| 09/30/2022 | 11/08/2022 | 10-Q |
| 06/30/2022 | 08/09/2022 | 10-Q |
| 03/31/2022 | 05/10/2022 | 10-Q |
| 12/31/2021 | 03/15/2022 | 10-K |
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Tendler, Ely D | General Counsel and Secretary | Direct | Sell | 12162025 | 0.91 | 16,850 | 15,334 | 235,503 | Form |
| 2 | Burdiek, Michael J | Direct | Buy | 5232025 | 1.33 | 10,000 | 13,300 | 853,275 | Form | |
| 3 | Burdiek, Michael J | Direct | Buy | 5152025 | 1.43 | 15,000 | 21,450 | 903,131 | Form | |
| 4 | Klasko, Stephen K Md | Direct | Buy | 5142025 | 1.49 | 15,000 | 22,350 | 22,350 | Form | |
| 5 | Sugrue, Stephen | Chief Compliance Officer | Direct | Buy | 5142025 | 1.44 | 10,000 | 14,400 | 514,552 | Form |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.